Dissolution Media for Drug Elution from Polymeric Matrices
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing drug elution from polymeric matrices in medical devices are inefficient, particularly for water-soluble drugs like dexamethasone sodium phosphate, and lack effective means to control manufacturing variability and quality assurance, leading to prolonged testing times and potential inconsistencies in elution profiles.
Innovation Solution
A unique dissolution media comprising 20-40% isopropyl alcohol, 0.2-6% matrix swelling agents such as diisopropyl amine, and a phosphate buffer at pH 6-8 is used to enhance the elution of compounds like dexamethasone sodium phosphate from polymeric matrices, allowing for accelerated in-vitro studies and quality control, along with an apparatus to minimize evaporation and ensure accurate sampling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional dissolution media are used for eluting water-soluble drugs from polymeric matrices, then the testing process is simple to perform, but the elution efficiency is poor and testing time is prolonged
Solution Approach 1:
The patent modifies the chemical composition parameters of the dissolution media by incorporating specific lower alkanols (20-40%), matrix swelling agents (0.2-6.0%), and buffers (pH 6-8). This parameter optimization enables efficient elution of water-soluble drugs like dexamethasone sodium phosphate from polymeric matrices within a practical testing timeframe, resolving the contradiction between elution efficiency and testing duration.
2Productivity
If accelerated in-vitro elution studies are conducted to reduce testing time, then productivity improves, but manufacturing variability and quality control become more difficult to manage
Solution Approach 1:
The patent implements a controlled dissolution testing system that monitors elution profiles under standardized conditions (specific media composition, temperature, agitation). This feedback mechanism allows for detection and correction of manufacturing variability, enabling accelerated testing while maintaining quality control and consistency in elution profiles.
Solution Approach 2:
By optimizing and standardizing the dissolution media parameters (lower alkanol concentration, swelling agent concentration, pH buffer), the patent creates a reproducible testing environment that accelerates elution while maintaining consistency. The standardized parameters ensure that manufacturing variability can be detected and controlled.
3Productivity
If matrix swelling agents are added to enhance drug elution, then elution efficiency improves, but the complexity of the dissolution media increases
Solution Approach 1:
The patent introduces matrix swelling agents at optimized concentrations (0.2-6.0%) to enhance drug elution from polymeric matrices. While this adds a component to the media formulation, the concentration range is carefully controlled to balance effectiveness with manageable complexity. The swelling agents work synergistically with the lower alkanols and buffers to achieve efficient elution without requiring overly complex media compositions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and controlled elution studies, reducing testing time and variability, and ensuring consistent elution profiles, thereby improving the manufacturing process and quality control of drug-eluting medical devices.
Implementation Method 1
A unique dissolution media comprising 20-40% isopropyl alcohol, 0.2-6% matrix swelling agents such as diisopropyl amine, and a phosphate buffer at pH 6-8 is used to enhance the elution of compounds like dexamethasone sodium phosphate from polymeric matrices
Implementation Method 2
This approach enables efficient and controlled elution studies, reducing testing time and variability, and ensuring consistent elution profiles
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Embodiments of the invention provide to apparatuses and media used in drug elution studies and methods for making and using them. One embodiment of the invention is a drug elution method that can be used for in-vitro studies of a matrix impregnated with a compound such as a drug blended polymer matrix. Such methods and materials can be used for example to assess and control the manufacturing process variability of drug eluting implantable devices such as cardiac leads.